LAMICTAL Drug Patent Profile

When do Lamictal patents expire, and when can generic versions of Lamictal launch?

Lamictal is a drug marketed by Glaxosmithkline Llc and is included in four NDAs. There is one patent protecting this drug.

The generic ingredient in LAMICTAL is lamotrigine. There are thirty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lamictal

A generic version of LAMICTAL was approved as lamotrigine by DR REDDYS LABS LTD on January 22^nd, 2009.

Summary for LAMICTAL

US Patents:	0
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	95
Patent Applications:	5,903
Drug Prices:	Drug price information for LAMICTAL
Drug Sales Revenues:	Drug sales revenues for LAMICTAL
What excipients (inactive ingredients) are in LAMICTAL?	LAMICTAL excipients list
DailyMed Link:	LAMICTAL at DailyMed

See drug prices for LAMICTAL

See drug sales revenues for LAMICTAL

Recent Clinical Trials for LAMICTAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BioPharma Services Inc.	PHASE1
Desitin Arzneimittel GmbH	PHASE1
Dr Cipto Mangunkusumo General Hospital	Phase 4

See all LAMICTAL clinical trials

Pharmacology for LAMICTAL

Drug Class	Anti-epileptic Agent Mood Stabilizer
Mechanism of Action	Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for LAMICTAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-005	Dec 27, 1994	AB	RX	Yes	Yes
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-004	May 29, 2009	AB	RX	Yes	Yes	8,637,512		Y
Glaxosmithkline Llc	LAMICTAL CD	lamotrigine	TABLET, FOR SUSPENSION;ORAL	020764-004	Sep 8, 2000	AB	RX	Yes	No

Expired US Patents for LAMICTAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-005	Dec 27, 1994	4,602,017*PED
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-004	Dec 27, 1994	4,602,017*PED
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-006	Dec 27, 1994	4,602,017*PED

International Patents for LAMICTAL

See the table below for patents covering LAMICTAL around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	8500062	1,2,4-TROAZOME DERIOVATIVES, PROCESS FOR PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
New Zealand	193890	3,5-DIAMINO-6-(SUBSTITUTED PHENYL)-1,2,4-TRIAZINES AND PHARMACEUTICAL COMPOSITIONS
Denmark	233880

Supplementary Protection Certificates for LAMICTAL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0021121	94C0016	Belgium		94C0016, 19941006

Market Dynamics and Financial Trajectory for Lamictal (Lamotrigine)

Last updated: January 11, 2026

Executive Summary

Lamictal (lamotrigine) is a widely prescribed anticonvulsant and mood stabilizer primarily used for epilepsy and bipolar disorder. Over the past decade, the drug has experienced shifts driven by evolving clinical guidelines, competitive landscape, patent protections, and regulatory changes. This report analyzes the current market environment, growth drivers, competitive pressures, patent landscape, and financial outlook, providing an authoritative understanding for stakeholders.

Introduction

Lamictal, developed by GlaxoSmithKline (GSK) and later acquired and marketed by Teva Pharmaceuticals and others, remains a key player in the neuropsychiatric therapeutic market. The drug's core indications—epilepsy and bipolar disorder—are characterized by significant global prevalence and unmet needs, which influence market dynamics. The global lamotrigine therapeutic market was valued at over USD 2.5 billion in 2022, with an expected compound annual growth rate (CAGR) of approximately 4.5% from 2023 to 2030.

---

What Are the Key Market Drivers and Constraints?

Market Drivers

Driver	Explanation	Data/Trend
Rising Prevalence of Epilepsy and Bipolar Disorder	Globally increasing diagnosed cases due to improved detection	Over 50 million epilepsy cases worldwide (WHO, 2021); bipolar disorder affects approximately 1-3% of global population (WHO, 2022)
Expanding Off-Label and Extended Uses	Emerging evidence supports use in migraine, neuropathic pain	Growing off-label prescriptions augment demand
Advancements in Formulations	Extended-release (ER) and flexible dosing options increase adherence	ER formulations launched in 2016, leading to improved compliance
Increasing Generic Competition	Price sensitivity enhances accessible options	Generics account for >80% of prescriptions in the EU and US

Market Constraints

Constraint	Explanation	Impact
Patent Expiry and Generics	Limited exclusivity after patent expiry in major markets	Erosion of revenue streams; generic entrance led to price drops (~80% reduction) post-2017
Regulatory and Safety Concerns	Risk of serious skin reactions (e.g., Stevens-Johnson syndrome)	Limits broader off-label uses; necessitates careful monitoring
Competitive Drugs	New antiepileptics and mood stabilizers entering the market	Drugs like levetiracetam, oxcarbazepine, and atypical antipsychotics compete for prescription share

---

Patent and Regulatory Landscape

Patent Timeline & Expiry

Patent Type	Original Patent	Expiry Date	Post-Patent Strategies
Composition of Matter	Filed 1988; issued 1991	2017 (US); 2018 (EU)	Transition to generics
Formulation Patents	ER formulations filed 2005	2021–2023	Patent "evergreening" strategies.
Use Patents	New indications filed 2011	2024–2026	Orphan indications considered to extend market exclusivity

Market Impact of Patent Expiry

• US Market: Generic entry in 2017 declined prices by 80%, with sales dropping from USD 800 million (2016) to USD 150 million (2018).
• EU Market: Similar decline observed post-2018 patent expiry.

Regulatory Changes & Approvals

• FDA: Approved in 1994 for epilepsy; extended approval for bipolar disorder in 2003.
• EMA: Approved around the same period, with subsequent indications (e.g., Lennox-Gastaut syndrome).
• Off-Label Approvals: Conditions like migraine prophylaxis are not officially approved but prescribed off-label, influencing market expansion.

---

Competitive Landscape

Key Players	Market Share (2022)	Products	Unique Strategies
GlaxoSmithKline	Pre-patent expiry dominance	Original Lamictal	Patent protections (until 2017)
Teva Pharmaceuticals	Major generic manufacturer	Generic lamotrigine	Price competition, authorized generics
Mylan and Sandoz	Significant generics	Lamotrigine	Focus on cost leadership
Novel Entrants	Limited, primarily biosimilars and newer agents	Few	Focus on combination therapies, digital health

Major Product Categories

Product Type	Examples	Market Penetration	Notes
Branded	Lamictal (GSK)	High (pre-2017)	Brand loyalty and physician preference
Generics	Multiple manufacturers	Dominant post-2017	Price-sensitive market share
Extended-Release Formulations	Lamictal XR	Growing	Improved compliance

Financial Trajectory and Future Outlook

Historical Revenue & Sales Data (US & Global)

Year	Revenue (USD billion)	Notes	Source
2015	2.0	Peak before patent expiry	[1]
2016	2.2	Slight growth	[1]
2017	0.8	Patent expiry; generic entry	[2]
2018	0.3	Market slump	[3]
2022	2.4	Post-generic stabilization	[4]

Market Forecast (2023–2030)

Year	Projected Revenue (USD billion)	CAGR	Key Assumptions
2023	2.5	4.5%	Stabilization of generic pricing, new indications
2025	2.8		Increased off-label use, digital health integration
2030	3.7		Entry into emerging markets, biosimilar proliferation

Revenue Breakdown by Region (2022)

Region	Share	Notes
North America	55%	Largest market due to high prevalence and approvals
Europe	25%	Growing generic penetration
Asia-Pacific	15%	Emerging market potential
Rest of World	5%	Untapped markets

---

Strategic Opportunities and Risks

Opportunities

• Novel Formulations: Focus on bioavailability and patient adherence.
• New Indications: Pursuing FDA and EMA approvals for migraine and neuropathic pain.
• Biosimilars & Generics: Price competition to regain market share.
• Digital Health Integration: Use of compliance tracking and telemedicine.

Risks

• Patent Litigation or Patent Challenges: Potential for legal delays or patent invalidations.
• Regulatory Setbacks: Issues with safety signals or slow approvals for new indications.
• Market Saturation & Price Erosion: Limited profitability post-generic entry.

---

Comparative Analysis: Lamictal vs. Competitors

Indicator	Lamictal	Top Competitors	Notes
Indications	Epilepsy, bipolar	Epilepsy, mood disorders	Wide regulatory approval
Market Share (2022)	20%	Varies, e.g., 15–25%	Established presence, patent protections
Price Point	USD 10–15 per tablet (brand)	Similar market prices	Generics reduce costs post-2017
Safety Profile	Well-characterized	Similar, with some newer agents	Skin reactions, neurotoxicity

---

Regulatory and Policy Considerations

Aspect	Detail	Impact
Off-Label Use Regulations	Managed by FDA/EMA	Limits billing and insurance coverage without approved indications
Pricing Policies	Price controls in some countries	Affect profitability
Patent Laws	Vary by jurisdiction	Impact on generic entry timing
Orphan Drug Designation	For certain indications	Can extend market exclusivity

---

Key Takeaways

• Post-2017 patent expiry significantly disrupted Lamictal’s revenue, with generic competition driving prices and sales down.
• The global market is recovering through increased off-label use, new formulations, and emerging indications.
• North America remains the dominant revenue region, though growth prospects in Asia-Pacific and developing markets are promising.
• The future trajectory hinges on new indication approvals, biosimilar/digital health integration, and strategic patent management.
• Market players must navigate patent expiries, safety concerns, and competitive pressures to sustain profitability.

---

FAQs

1. How has patent expiry impacted Lamictal’s market share?
Patent expiry in 2017 led to a significant drop in branded sales, with generics capturing over 80% of prescriptions, reducing revenue from USD 2.2 billion (2016) to USD 0.8 billion (2017). Market share shifted primarily to generic manufacturers.

2. What are the main growth drivers post-patent expiry?
Growth stems from off-label uses (e.g., migraine prevention), newer formulations like XR, expansion into emerging markets, and potential new indications approved by regulators.

3. How does Lamictal compare to its competitors in terms of safety?
Lamictal’s safety profile is well-established, with risks such as Stevens-Johnson syndrome. Some newer drugs offer different safety profiles but may have other adverse effects, influencing prescribing decisions.

4. What regulatory challenges does Lamictal face in extending its market?
Safety signals, patent challenges, and approval for new indications remain key hurdles. Ongoing regulatory scrutiny around off-label use and safety data may influence expansion strategies.

5. What is the outlook for Lamictal’s revenue in the next decade?
Projected CAGR of approximately 4.5%, with revenues reaching USD 3.7 billion by 2030, supported by new indications, market expansion, and innovation in formulations.

---

References

[1] IQVIA, 2015 Data Summary.
[2] U.S. FDA Drug Approvals, 2017 Report.
[3] MarketWatch Reports, 2018.
[4] GlobalData, 2022 Industry Overview.